Natera, Inc. NTRA

What this company does

Natera commercializes personalized blood-based DNA tests used in oncology for therapy decisions from diagnosis through survivorship, develops and commercializes non- or minimally invasive tests for women's health needs such as prenatal testing and hereditary cancer screening, and offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease. It is headquartered in Austin, Texas, with laboratory facilities located in Austin, Texas, San Carlos, California, and Boulder, Colorado. Its revenues were $2,306.1 million in 2025, compared with $1,696.9 million in 2024 and $1,082.6 million in 2023. It processed approximately 3.5 million tests in 2025, compared with approximately 3.1 million tests in 2024 and 2.5 million tests in 2023. In addition to its direct sales force in the United States, it has a global network of over 100 laboratory and distribution partners. As of December 31, 2025, its global workforce comprised 6,140 employees, of whom 6,135 were full-time employees. Its Signatera circulating tumor DNA (ctDNA) test is custom designed for, informed by, and specific to the tumor DNA of each patient. It launched Panorama, its non-invasive prenatal test (NIPT), in 2013; Panorama helps physicians assess the risk of fetal genetic abnormalities by non-invasively screening for fetal chromosomal abnormalities, including Down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, and triploidy.

Written from the business description in Natera, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.